- Home
- AZ vs TNYA Comparison
AZ vs TNYA Comparison
Compare AZ & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AZ | TNYA |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.5M | 234.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AZ | TNYA |
|---|---|---|
| Price | $6.48 | $0.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $20.00 | $7.80 |
| AVG Volume (30 Days) | 475.6K | ★ 7.5M |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,463,000.00 | N/A |
| Revenue This Year | $1,343,857.60 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 41.45 | N/A |
| 52 Week Low | $5.00 | $0.36 |
| 52 Week High | $12.36 | $2.35 |
Technical Indicators
Market Signals| Indicator | AZ | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 56.19 | 32.00 |
| Support Level | $5.64 | $0.66 |
| Resistance Level | $6.59 | $0.76 |
| Average True Range (ATR) | 0.47 | 0.09 |
| MACD | 0.09 | -0.02 |
| Stochastic Oscillator | 75.00 | 6.76 |
Price Performance
Historical ComparisonAbout AZ A2Z Smart Technologies Corp.
A2Z Cust2Mate Solutions Corp is engaged in creating shopping carts. With the help of a user-friendly smart algorithm, touch screen, and other technologies, the company streamlines the retail shopping experience by scanning purchased products and enabling in-cart payment so that customers can simply pick & go, and bypass long cashier checkout lines.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.